CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Read More
Please complete the form below to submit your question or request.
Note to Patients and Caregivers:
The form below is for Healthcare Professionals only. To obtain information about CAYSTON,
please visit our patient website or speak with your doctor.
* Required field
CAYSTON is contraindicated in patients with a known allergy to aztreonam.
CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.
Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.
Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV1) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.
Decreases in FEV1 After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV1 during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV1 declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV1 measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV1 are caused by a pulmonary exacerbation.
Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.
Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.
CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.
Please click here to see full Prescribing Information.
The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.
ALLY, CAYSTON, the CAYSTON logo, CAYSTON ACCESS PROGRAM, the CAYSTON ACCESS PROGRAM logo, GILEAD, the GILEAD logo, and MY CAYSTON COMMUNITY are trademarks of Gilead Sciences, Inc. ALTERA is a registered trademark of PARI Pharma GmbH. All other trademarks referenced herein are the property of their respective owners.
©2023 Gilead Sciences, Inc. All rights reserved. US-CAYP-0035 02/23
*Each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.6
†These questions are from the CFQ-R version for patients 14 years and older; younger children used a different questionnaire or a parent questionnaire was used. Minimum clinically important difference was not established for the child/parent questionnaire.
X
DID YOU KNOW?
These 3 bugs represent coughing, wheezing, and mucus production; 3 of the breathing symptoms you may experience if you have Pa.
TIP:
Do not change your dose or stop taking CAYSTON unless your healthcare provider tells you to.
This is how the study was designed, before it began.
This is also referred to as a "double-blind" study.
Even though people were off treatment, they were still being monitored for the study.
People gave answers from a 4-point scale to communicate to their doctors how they were feeling.
TIP:
Track how you're feeling with a daily journal. Ask yourself these questions and talk to your doctor about symptoms you're experiencing.
"Breathing symptoms" include wheezing, coughing, and mucus production.
This means that even after people stopped taking CAYSTON, they still reported an improvement in their wheezing, coughing, and mucus production compared to placebo at Day 42, though the difference was smaller.
It’s so important for the Pa medication to improve his FEV1 —it gives you the encouragement to keep going.
Annie (caretaker for Gareth, age 8, treated with CAYSTON)
Day 28 was the predetermined timepoint used to measure improvement.
FYI:
This means how much air can be exhaled in one second in liters.
Currently taking CAYSTON and have questions for your care team?
Download a Conversation Guide
IMPORTANT:
Talk to your doctor if you experience new or worsening symptoms while taking CAYSTON.
This is how the study was designed, before it began.
This means that the study was not used in the evaluation and not taken into consideration for the FDA approval of CAYSTON. The information will not be found in the package insert.
The 3 numbers across each treatment course were averaged to calculate the actual change in lung function.
Considering CAYSTON and have questions for your care team?
Download a Conversation Guide
This study was set up to only look at results from one time point.
Managing CF with my care team means educating myself about treatment options and playing an active, central role as a member of my care team.
Chris Kvam
Learn how Chris talks about treatment options with his care team.
Hear from Chris
IMPORTANT:
Tell your doctor if you have
any new or worsening
symptoms while taking
CAYSTON and about any
side effects that bother you
or that do not go away.
Want more tips for fitting
CAYSTON into your day?
Get tips
Learn about dosing and
administration with
CAYSTON.
Get the guide
Watch a video about how
CAYSTON and the
ALTERA® Nebulizer work.
Watch now
See how to properly mix and
store your CAYSTON
treatment.
View now
As someone who works full-time, has a family, and likes to travel, flexibility is the key to managing my treatment regimen.
Mark
See how Mark takes his treatment on the go
Use the Cayston Access
Program Enrollment Form
to get started.
Download now
Get familiar with the resources that
can help you start and stay on track
with CAYSTON.
Download the Resource Guide
Download this Clinical
Data Overview.
Download now
More questions about
CAYSTON?
Read the FAQs
DID YOU KNOW?
You can get resources sent
straight to your inbox.
Visit My Cayston Community
CAYSTON is contraindicated in patients with a known allergy to aztreonam.
CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.
Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.
Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV1) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.
Decreases in FEV1 After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV1 during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV1 declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV1 measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV1 are caused by a pulmonary exacerbation.
Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.
Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.
CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.
Please click here to see full Prescribing Information.
